Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Kiniksa Pharmaceuticals ( (KNSA) ) has provided an update.
Kiniksa Pharmaceuticals has expanded its Board of Directors from nine to ten members with the appointment of M. Cantey Boyd. Boyd, who brings a wealth of experience from her time at Baker Bros. Advisors LP and prior role at Deutsche Bank Securities, will join the Compensation Committee and Class III directors. Her financial expertise and life sciences industry knowledge are expected to greatly benefit the company. She will be compensated according to the company’s standard non-employee director program and has entered into the same indemnification agreement as her fellow directors.
For a thorough assessment of KNSA stock, go to TipRanks’ Stock Analysis page.
